Who is sponsoring NCT05229588?

NCT05229588 is sponsored by HonorHealth Research Institute.

What drugs are being tested in NCT05229588?

Interventions in NCT05229588: Lurbinectedin 4 MG Injection [Zepzelca].

What condition does NCT05229588 study?

NCT05229588 studies Gastrointestinal Malignancies.

Is NCT05229588 still recruiting?

NCT05229588 is currently completed. Last updated 15 August 2025.

Last reviewed 2025-08-15 · How we verify

NCT05229588

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

Completed Phase 2 Last updated 15 August 2025

What this trial tests

Phase 2 trial testing Lurbinectedin 4 MG Injection [Zepzelca] in Gastrointestinal Malignancies in 8 participants. Completed in 4 August 2025.

Timeline

14 June 2022

Primary endpoint
4 August 2025

4 August 2025

Quick facts

Lead sponsor	HonorHealth Research Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	14 June 2022
Primary completion	4 August 2025
Estimated completion	4 August 2025
Sites	1 location across United States

Drugs / interventions tested

Lurbinectedin 4 MG Injection [Zepzelca] — full drug profile →

Conditions studied

Gastrointestinal Malignancies — all drugs for Gastrointestinal Malignancies →

Sponsor

HonorHealth Research Institute

Who can join

18 and older, any sex, with Gastrointestinal Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS, Pellat A, Brezault C, Dhooge M, et al · · 2022 · cited 22× · PMID 36399952 · DOI 10.1016/j.esmoop.2022.100638
Marine natural products as a source of novel anticancer drugs: an updated review (2019-2023).
El-Seedi HR, Refaey MS, Elias N, El-Mallah MF, et al · · 2025 · cited 16× · PMID 39853457 · DOI 10.1007/s13659-024-00493-5
Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC).
Liu R, Li J, Liu L, Wang W, et al · · 2025 · cited 6× · PMID 40458305 · DOI 10.1016/j.cpt.2024.07.004
Innate Immunity and Platelets: Unveiling Their Role in Chronic Pancreatitis and Pancreatic Cancer.
Blümke J, Schameitat M, Verma A, Limbecker C, et al · · 2025 · cited 2× · PMID 40427186 · DOI 10.3390/cancers17101689

Verify or expand the search:

Other trials of Lurbinectedin 4 MG Injection [Zepzelca]

Trials testing the same drug.

NCT07121478 — Patients With High-grade Pancreatic Neuroendocrine Tumors · Phase 2 · enrolling by invitation

Other recruiting trials for Gastrointestinal Malignancies

Currently open trials in the same condition.

NCT06644274 — The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies · recruiting

Other HonorHealth Research Institute trials

Trials by the same sponsor.

NCT05216120 — Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas · Phase 2 · withdrawn
NCT05004025 — Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma · Phase 1 · completed
NCT04611139 — Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers · Phase 1 · withdrawn
NCT05175521 — Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine · NA · completed
NCT05068752 — Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05229588 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by HonorHealth Research Institute
Last refreshed: 15 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05229588.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing